RT期刊文章SR电子T1髓少突细胞糖蛋白抗体与双边和复发性视神经炎和多发性硬化症有不同的辐射资料或Aquaporin-4 Antibody-associated视神经炎(P3.001)摩根富林明神经病学神经学乔FD Lippincott Williams &威尔金斯SP P3.001 VO 86是16补充A1 Sudarshini拉马纳坦A1克里斯蒂娜测前A1伊丽莎白·巴恩斯A1以斯帖Tantsis A1 Stephen Reddel A1安德鲁·亨德森A1 Ostoja Vucic A1马克戈尔曼A1莱斯利·本森A1 Gula首页y高山A1凯瑟琳赖尼A1迈克尔·巴内特A1约翰Parratt A1托德·哈迪A1理查德·莱维A1维拉Merheb A1玛格丽塔Nosadini A1冯国经A1 Fabienne Brilot A1罗素戴尔年2016 UL //www.ez-admanager.com/content/86/16_Supplement/P3.001.abstract AB目的:我们进行第一集视神经炎的临床和放射学描述(上)患者髓少突细胞糖蛋白Antibody-associated (MOG-ON), Aquaporin-4 Antibody-associated (AQP4-ON),和多发性硬化症(毫秒)。我们提出会有特定的放射性预测根据的原因。背景:早期识别的病因和预后影响治疗决策。设计/方法:我们进行了以流式细胞术测定使用HEK293细胞表达完整的人类生活MOG测试血清23成人AQP4 antibody-negative neuromyelitis视谱系障碍。蒙蔽neuroradiological评估随后进行磁共振成像的50个患者(平均年龄24岁,射程3-58,41岁女性)的第一集,包括MOG-ON (n = 19), AQP4-ON (n = 11),毫秒(n = 13)和非保密(n = 7)。结果:MOG抗体检测在9/23的病人,他们举行了双边。MOG-ON患者更有可能复发,是类固醇响应。两国参与在MOG-ON更为常见,AQP4-ON比毫秒(84 v (percnt)。82 (percnt) 23节[percnt]),视神经头部肿胀更常见于MOG-ON (53 percnt v。9 [percnt] v.0 [percnt]),交叉的更为普遍参与AQP4-ON (5 v (percnt)。64年[percnt] v.15 [percnt]),和双边视神经束更为普遍参与AQP4-ON (0 v (percnt)。45 [percnt] v.0 [percnt])。 Retrobulbar optic nerve involvement was more common in MOG-ON, whereas intracranial optic nerve involvement was more common in AQP4-ON. MOG-ON and AQP4-ON had longer lesion lengths and lesion extent scores than MS-ON. AQP4-ON more frequently had severe and sustained visual impairment. Conclusions: MOG antibodies are associated with a bilateral ON phenotype and are steroid responsive. MOG and AQP4-ON are frequently bilateral and longitudinally extensive, compared with MS-ON. MOG-ON tends to involve the anterior optic pathway whereas AQP4-ON tends to involve the posterior optic pathway. These radiological predictors may expedite diagnosis at the first presentation of ON, with therapeutic and prognostic implications.Disclosure: Dr. Ramanathan has received personal compensation from NHMRC Australia and the Petre Foundation. Dr. Prelog has nothing to disclose. Dr. Barnes has nothing to disclose. Dr. Tantsis has nothing to disclose. Dr. Reddel has received research support from Genzyme Sanofi, Biogen, CSL, and Baxter. Dr. Henderson has nothing to disclose. Dr. Vucic has received research support from Biogen Idec, Novartis, Bayer, CSL, and Genzyme. Dr. Gorman has nothing to disclose. Dr. Benson has nothing to disclose. Dr. Alper has nothing to disclose. Dr. Riney has received research support from Novartis. Dr. Barnett has received research support from Novartis Pharmaceuticals. Dr. Parratt has received research support from Multiple Sclerosis Research Australia, Genzyme, Novartis, Merck Serono and Bayer Schering, Biogen Idec and CSL. Dr. Hardy has nothing to disclose. Dr. Leventer has nothing to disclose. Dr. Merheb has nothing to disclose. Dr. Nosadini has nothing to disclose. Dr. Fung has nothing to disclose. Dr. Brilot-Turville has received research support from Star Scientic Foundation, Trish MS Research Foundation, MSRA, MS Angels Melbourne, NHMRC, and the Petre Foundation. Dr. Dale has received research support from Star Scientific Foundation, Trish MS Research Foundation, MSRA, NHMRC Australia, and the Petre Foundation.Monday, April 18 2016, 8:30 am-7:00 pm